News Conference News ACC 2024 NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year Yael L. Maxwell July 03, 2024
News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
News Conference News ACC 2024 HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players Michael O'Riordan April 15, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News ACC 2024 BE ACTIVE: Gaming for Points and Money Can Boost Step Counts L.A. McKeown April 11, 2024
News Conference News ACC 2024 Need a Statin for Primary Prevention? There’s an App for That Michael O'Riordan April 10, 2024
News Conference News ACC 2024 Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL Yael L. Maxwell April 09, 2024
News Conference News ACC 2024 PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE L.A. McKeown April 08, 2024
Presentation ACC 2024 Evaluation of a Technology Assisted Web Application to Qualify for Nonprescription Statin Administration Presenter: Steven E. Nissen April 08, 2024
Presentation ACC 2024 PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques Presenter: Seung-Jung Park April 07, 2024
Presentation ACC 2024 Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial Presenter: Alexander Fanaroff April 07, 2024
News Conference News ACC 2024 Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT Caitlin E. Cox April 06, 2024
Presentation ACC 2024 Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk Presenter: Ronald Chi Hang Lee April 06, 2024
Presentation ACC 2024 Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Presenter: Michael J. Koren April 06, 2024
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024